Do analysts rate PBM or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PBM or SCLX more profitable?

Psyence Biomedical has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Scilex -1,414.57% N/A -147.00%

Do analysts recommend PBM or VERU?

Veru has a consensus target price of $24.50, indicating a potential upside of 947.01%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is PBM or VERU more profitable?

Psyence Biomedical's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Veru N/A -47.58% -35.83%

Does the media prefer PBM or VERU?

In the previous week, Veru had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 6 mentions for Veru and 5 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 0.94 beat Veru's score of 0.16 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend PBM or FLNA?

Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 595.60%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, PBM or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.24 Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is PBM or FLNA more profitable?

Psyence Biomedical's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Cassava Sciences N/A -58.78% -36.74%

Do analysts prefer IXHL or PBM?

Incannex Healthcare presently has a consensus price target of $18.00, suggesting a potential upside of 447.11%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IXHL or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Psyence Biomedical N/A N/A N/A

Does the media favor IXHL or PBM?

In the previous week, Psyence Biomedical had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for Psyence Biomedical and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.94 beat Psyence Biomedical's score of 0.94 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PBM or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 618.75%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Is PBM or KPTI more profitable?

Psyence Biomedical has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Karyopharm Therapeutics -153.28% N/A -145.18%

Psyence Biomedical (PBM) Competitors

$6.00 +0.60 (+11.11%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$5.97 -0.03 (-0.50%)

As of 04:58 AM Eastern

Compare

PBM vs. SCLX, VERU, FLNA, IXHL, and KPTI

Should you buy Psyence Biomedical stock or one of its competitors? Psyence Biomedical's main competitors and comparable companies include Scilex (SCLX), Veru (VERU), Cassava Sciences (FLNA), Incannex Healthcare (IXHL), and Karyopharm Therapeutics (KPTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Psyence Biomedical compare to Scilex?

Psyence Biomedical (NASDAQ:PBM) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Psyence Biomedical has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Scilex	-1,414.57%	N/A	-147.00%

Psyence Biomedical has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.24
Scilex	$30.25M	1.43	-$358.73M	-$49.70	N/A

In the previous week, Psyence Biomedical had 4 more articles in the media than Scilex. MarketBeat recorded 5 mentions for Psyence Biomedical and 1 mentions for Scilex. Scilex's average media sentiment score of 1.89 beat Psyence Biomedical's score of 0.94 indicating that Scilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Scilex	Very Positive

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Psyence Biomedical has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Psyence Biomedical beats Scilex on 8 of the 11 factors compared between the two stocks.

How does Psyence Biomedical compare to Veru?

Psyence Biomedical (NASDAQ:PBM) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Veru had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 6 mentions for Veru and 5 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 0.94 beat Veru's score of 0.16 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Psyence Biomedical has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

Veru has a consensus target price of $24.50, indicating a potential upside of 947.01%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Psyence Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

Psyence Biomedical has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.24
Veru	$16.89M	2.36	-$22.73M	-$0.69	N/A

Summary

Psyence Biomedical beats Veru on 8 of the 14 factors compared between the two stocks.

How does Psyence Biomedical compare to Cassava Sciences?

Psyence Biomedical (NASDAQ:PBM) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, Psyence Biomedical had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 5 mentions for Psyence Biomedical and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.89 beat Psyence Biomedical's score of 0.94 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Cassava Sciences	Very Positive

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cassava Sciences is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.24
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Psyence Biomedical has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, meaning that its share price is 169% less volatile than the broader market.

Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 595.60%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Psyence Biomedical's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Cassava Sciences	N/A	-58.78%	-36.74%

Summary

Psyence Biomedical beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Psyence Biomedical has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	437.57	-$46.88M	-$1.55	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.24

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Psyence Biomedical's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Psyence Biomedical	N/A	N/A	N/A

In the previous week, Psyence Biomedical had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for Psyence Biomedical and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.94 beat Psyence Biomedical's score of 0.94 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Psyence Biomedical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a beta of 6.97, meaning that its stock price is 597% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market.

Incannex Healthcare presently has a consensus price target of $18.00, suggesting a potential upside of 447.11%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Psyence Biomedical beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does Psyence Biomedical compare to Karyopharm Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Psyence Biomedical has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.24
Karyopharm Therapeutics	$146.07M	0.25	-$196.04M	-$13.09	N/A

Psyence Biomedical has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Psyence Biomedical has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 618.75%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Psyence Biomedical had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 5 mentions for Psyence Biomedical and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.89 beat Psyence Biomedical's score of 0.94 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Karyopharm Therapeutics	Very Positive

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Psyence Biomedical beats Karyopharm Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.38M	$12.46B	$7.16B	$14.31B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	0.24	794.72	273.30	25.37
Price / Sales	N/A	761.06	617.12	74.54
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.81	10.43	10.42	6.24
Net Income	-$6.94M	$2.84B	$3.49B	$358.08M
7 Day Performance	26.58%	-2.40%	-1.16%	-0.70%
1 Month Performance	72.41%	1.35%	0.56%	-2.76%
1 Year Performance	-74.60%	4.49%	20.18%	6.72%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.3605 of 5 stars	$6.00 +11.1%	N/A	-73.6%	$12.38M	N/A	0.24	N/A	News Coverage
SCLX Scilex	0.6215 of 5 stars	$5.05 -2.9%	N/A	-80.6%	$44.16M	$30.25M	N/A	80	Positive News
VERU Veru	2.7119 of 5 stars	$2.50 +0.8%	$24.50 +880.0%	-32.2%	$42.28M	$16.89M	N/A	230
FLNA Cassava Sciences	2.0098 of 5 stars	$0.81 flat	$5.00 +518.1%	-65.9%	$39.08M	N/A	N/A	20	Positive News
IXHL Incannex Healthcare	2.068 of 5 stars	$3.25 +0.6%	$18.00 +453.8%	-80.0%	$38.65M	$90K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. SCLX, VERU, FLNA, IXHL, and KPTI

How does Psyence Biomedical compare to Scilex?

Summary

How does Psyence Biomedical compare to Veru?

Summary

How does Psyence Biomedical compare to Cassava Sciences?

Summary

How does Psyence Biomedical compare to Incannex Healthcare?

Summary

How does Psyence Biomedical compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. SCLX, VERU, FLNA, IXHL, and KPTI

How does Psyence Biomedical compare to Scilex?

Is PBM or SCLX more profitable?

Which has better earnings and valuation, PBM or SCLX?

Does the media prefer PBM or SCLX?

Do institutionals and insiders hold more shares of PBM or SCLX?

Which has more volatility & risk, PBM or SCLX?

Do analysts rate PBM or SCLX?

Summary

How does Psyence Biomedical compare to Veru?

Does the media prefer PBM or VERU?

Do insiders and institutionals hold more shares of PBM or VERU?

Which has more volatility and risk, PBM or VERU?

Do analysts recommend PBM or VERU?

Is PBM or VERU more profitable?

Which has higher valuation and earnings, PBM or VERU?

Summary

How does Psyence Biomedical compare to Cassava Sciences?

Does the media prefer PBM or FLNA?

Do insiders & institutionals believe in PBM or FLNA?

Which has preferable earnings & valuation, PBM or FLNA?

Which has more risk & volatility, PBM or FLNA?

Do analysts recommend PBM or FLNA?

Is PBM or FLNA more profitable?

Summary

How does Psyence Biomedical compare to Incannex Healthcare?

Which has better earnings and valuation, IXHL or PBM?

Do insiders and institutionals have more ownership in IXHL or PBM?

Is IXHL or PBM more profitable?

Does the media favor IXHL or PBM?

Which has more risk & volatility, IXHL or PBM?

Do analysts prefer IXHL or PBM?

Summary

How does Psyence Biomedical compare to Karyopharm Therapeutics?

Which has better valuation & earnings, PBM or KPTI?

Which has more risk & volatility, PBM or KPTI?

Is PBM or KPTI more profitable?

Do analysts rate PBM or KPTI?

Does the media refer more to PBM or KPTI?

Do institutionals & insiders hold more shares of PBM or KPTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools